https://orcid.org/0000-0002-5028-6567
Key Points
A high-resolution single-cell map of diagnostic CML bone marrow to annotate features of TKI resistance.
Gene expression signatures within the LSCs and NK cells are indicative of TKI response.
Abstract
Primary resistance to tyrosine kinase inhibitors (TKIs) is a significant barrier to optimal outcomes in chronic myeloid leukemia (CML), but factors contributing to response heterogeneity remain unclear. Using single-cell RNA (scRNA) sequencing, we identified 8 statistically significant features in pretreatment bone marrow, which correlated with either sensitivity (major molecular response or MMR) or extreme resistance to imatinib (eventual blast crisis [BC] transformation). Employing machine-learning, we identified leukemic stem cell (LSC) and natural killer (NK) cell gene expression profiles predicting imatinib response with >80% accuracy, including no false positives for predicting BC. A canonical erythroid-specifying (TAL1/KLF1/GATA1) regulon was a hallmark of LSCs from patients with MMR and was associated with erythroid progenitor [ERP] expansion in vivo (P < .05), and a 2- to 10-fold (6.3-fold in group A vs 1.09-fold in group C) erythroid over myeloid bias in vitro. Notably, ERPs demonstrated exquisite TKI sensitivity compared with myeloid progenitors (P < .001). These LSC features were lost with progressive resistance, and MYC- and IRF1-driven inflammatory regulons were evident in patients who progressed to transformation. Patients with MMR also exhibited a 56-fold expansion (P < .01) of a normally rare subset of hyperfunctional adaptive-like NK cells, which diminished with progressive resistance, whereas patients destined for BC accumulated inhibitory NKG2A+ NK cells favoring NK cell tolerance. Finally, we developed antibody panels to validate our scRNA-seq findings. These panels may be useful for prospective studies of primary resistance, and in assessing the contribution of predetermined vs acquired factors in TKI response heterogeneity.
References
1.
Rowley
JD
. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
. Nature
. 1973
;243
(5405
):290
-293
.2.
Braun
TP
, Eide
CA
, Druker
BJ
. Response and resistance to BCR-ABL1-targeted therapies
. Cancer Cell
. 2020
;37
(4
):530
-542
.3.
Holyoake
TL
, Vetrie
D
. The chronic myeloid leukemia stem cell: stemming the tide of persistence
. Blood
. 2017
;129
(12
):1595
-1606
.4.
Shanmuganathan
N
, Pagani
IS
, Ross
DM
, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
. Blood
. 2021
;137
(9
):1196
-1207
.5.
Hanfstein
B
, Shlyakhto
V
, Lauseker
M
, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
. Leukemia
. 2014
;28
(10
):1988
-1992
.6.
Iriyama
N
, Fujisawa
S
, Yoshida
C
, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group
. Am J Hematol
. 2015
;90
(4
):282
-287
.7.
Krishnan
V
, Kim
DDH
, Hughes
TP
, Branford
S
, Ong
ST
. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers
. Haematologica
. 2022
;107
(2
):358
-370
.8.
McWeeney
SK
, Pemberton
LC
, Loriaux
MM
, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
. Blood
. 2010
;115
(2
):315
-325
.9.
Yong
ASM
, Szydlo
RM
, Goldman
JM
, Apperley
JF
, Melo
JV
. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
. Blood
. 2006
;107
(1
):205
-212
.10.
Ko
TK
, Javed
A
, Lee
KL
, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
. Blood
. 2020
;135
(26
):2337
-2353
.11.
Hughes
A
, Clarson
J
, Tang
C
, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
. Blood
. 2017
;129
(9
):1166
-1176
.12.
Bruck
O
, Blom
S
, Dufva
O
, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
. Leukemia
. 2018
;32
(7
):1643
-1656
.13.
Hsieh
YC
, Kirschner
K
, Copland
M
. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
. Leukemia
. 2021
;35
(5
):1229
-1242
.14.
Schmidt
F
, Kern
F
, Ebert
P
, Baumgarten
N
, Schulz
MH
. TEPIC 2-an extended framework for transcription factor binding prediction and integrative epigenomic analysis
. Bioinformatics
. 2019
;35
(9
):1608
-1609
.15.
Aibar
S
, Gonzalez-Blas
CB
, Moerman
T
, et al. SCENIC: single-cell regulatory network inference and clustering
. Nat Methods
. 2017
;14
(11
):1083
-1086
.16.
Hou
R
, Denisenko
E
, Ong
HT
, Ramilowski
JA
, Forrest
ARR
. Predicting cell-to-cell communication networks using NATMI
. Nat Commun
. 2020
;11
(1
):5011
.17.
Pellin
D
, Loperfido
M
, Baricordi
C
, et al. A comprehensive single cell transcriptional landscape of human hematopoietic progenitors
. Nat Commun
. 2019
;10
(1
):2395
.18.
Psaila
B
, Wang
G
, Rodriguez-Meira
A
, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets
. Mol Cell
. 2020
;78
(3
):477
-492.e8
.19.
Velten
L
, Haas
SF
, Raffel
S
, et al. Human haematopoietic stem cell lineage commitment is a continuous process
. Nat Cell Biol
. 2017
;19
(4
):271
-281
.20.
Giladi
A
, Paul
F
, Herzog
Y
, et al. Single-cell characterization of haematopoietic progenitors and their trajectories in homeostasis and perturbed haematopoiesis
. Nat Cell Biol
. 2018
;20
(7
):836
-846
.21.
Eaves
C
, Cashman
J
, Eaves
A
. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia
. Leuk Res
. 1998
;22
(12
):1085
-1096
.22.
Oetjen
KA
, Lindblad
KE
, Goswami
M
, et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry
. JCI Insight
. 2018
;3
(23
):e124928
.23.
Thomson
DW
, Shahrin
NH
, Wang
PPS
, et al. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia
. Leukemia
. 2020
;34
(8
):2051
-2063
.24.
Modi
H
, McDonald
T
, Chu
S
, Yee
JK
, Forman
SJ
, Bhatia
R
. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
. Blood
. 2007
;109
(12
):5411
-5421
.25.
Jose-Eneriz
ES
, Roman-Gomez
J
, Cordeu
L
, et al. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia
. Br J Haematol
. 2008
;142
(4
):571
-582
.26.
Li
J
, Ge
Z
. High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia
. BMC Cancer
. 2021
;21
(1
):475
.27.
Kamal
AM
, El-Hefny
NH
, Hegab
HM
, El-Mesallamy
HO
. Expression of thioredoxin-1 (TXN) and its relation with oxidative DNA damage and treatment outcome in adult AML and ALL: a comparative study
. Hematology
. 2016
;21
(10
):567
-575
.28.
Kim
TM
, Ha
SA
, Kim
HK
, et al. Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
. Blood Cancer J
. 2011
;1
(8
):e32
.29.
Zipeto
MA
, Court
AC
, Sadarangani
A
, et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis
. Cell Stem Cell
. 2016
;19
(2
):177
-191
.30.
Ilander
M
, Olsson-Stromberg
U
, Schlums
H
, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
. Leukemia
. 2017
;31
(5
):1108
-1116
.31.
Mizoguchi
I
, Yoshimoto
T
, Katagiri
S
, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
. Cancer Sci
. 2013
;104
(9
):1146
-1153
.32.
Rea
D
, Henry
G
, Khaznadar
Z
, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
. Haematologica
. 2017
;102
(8
):1368
-1377
.33.
Schutz
C
, Inselmann
S
, Saussele
S
, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
. Leukemia
. 2017
;31
(4
):829
-836
.34.
Dann
E
, Henderson
NC
, Teichmann
SA
, Morgan
MD
, Marioni
JC
. Differential abundance testing on single-cell data using k-nearest neighbor graphs
. Nat Biotechnol
. 2022
;40
(2
):245
-253
.35.
Chang
MC
, Cheng
HI
, Hsu
K
, et al. NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia
. Front Immunol
. 2018
;9
:3152
.36.
Giustacchini
A
, Thongjuea
S
, Barkas
N
, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
. Nat Med
. 2017
;23
(6
):692
-702
.37.
Mead
AJ
, Mullally
A
. Myeloproliferative neoplasm stem cells
. Blood
. 2017
;129
(12
):1607
-1616
.38.
Haas
S
, Trumpp
A
, Milsom
MD
. Causes and consequences of hematopoietic stem cell heterogeneity
. Cell Stem Cell
. 2018
;22
(5
):627
-638
.39.
Watcham
S
, Kucinski
I
, Gottgens
B
. New insights into hematopoietic differentiation landscapes from single-cell RNA sequencing
. Blood
. 2019
;133
(13
):1415
-1426
.40.
Zeng
AGX
, Bansal
S
, Jin
L
, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
. Nat Med
. 2022
;28
(6
):1212
-1223
.41.
Nandakumar
SK
, Ulirsch
JC
, Sankaran
VG
. Advances in understanding erythropoiesis: evolving perspectives
. Br J Haematol
. 2016
;173
(2
):206
-218
.42.
Park
SM
, Cho
H
, Thornton
AM
, et al. IKZF2 drives leukemia stem cell self-renewal and inhibits myeloid differentiation
. Cell Stem Cell
. 2019
;24
(1
):153
-165.e7
.43.
Crinier
A
, Dumas
PY
, Escaliere
B
, et al. Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
. Cell Mol Immunol
. 2021
;18
(5
):1290
-1304
.44.
Yang
C
, Siebert
JR
, Burns
R
, et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome
. Nat Commun
. 2019
;10
(1
):3931
.45.
Kamiya
T
, Seow
SV
, Wong
D
, Robinson
M
, Campana
D
. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
. J Clin Invest
. 2019
;129
(5
):2094
-2106
.46.
Borst
L
, van der Burg
SH
, van Hall
T
. The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment
. Clin Cancer Res
. 2020
;26
(21
):5549
-5556
.47.
Myers
JA
, Miller
JS
. Exploring the NK cell platform for cancer immunotherapy
. Nat Rev Clin Oncol
. 2021
;18
(2
):85
-100
.48.
Cerwenka
A
, Lanier
LL
. Natural killer cell memory in infection, inflammation and cancer
. Nat Rev Immunol
. 2016
;16
(2
):112
-123
.49.
Sun
JC
, Beilke
JN
, Lanier
LL
. Adaptive immune features of natural killer cells
. Nature
. 2009
;457
(7229
):557
-561
.50.
Branford
S
, Kim
DDH
, Apperley
JF
, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
. Leukemia
. 2019
;33
(8
):1835
-1850
.51.
Kim
T
, Tyndel
MS
, Kim
HJ
, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
. Blood
. 2017
;129
(1
):38
-47
.52.
Takahashi
N
, Miura
I
, Saitoh
K
, Miura
AB
. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization
. Blood
. 1998
;92
(12
):4758
-4763
.53.
Pagani
IS
, Dang
P
, Saunders
VA
, et al. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
. Leukemia
. 2020
;34
(4
):1052
-1061
.54.
Thielen
N
, Richter
J
, Baldauf
M
, et al. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy
. Clin Cancer Res
. 2016
;22
(16
):4030
-4038
.55.
Houshmand
M
, Simonetti
G
, Circosta
P
, et al. Chronic myeloid leukemia stem cells
. Leukemia
. 2019
;33
(7
):1543
-1556
.56.
Warfvinge
R
, Geironson
L
, Sommarin
MNE
, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
. Blood
. 2017
;129
(17
):2384
-2394
.57.
Mori
Y
, Chen
JY
, Pluvinage
JV
, Seita
J
, Weissman
IL
. Prospective isolation of human erythroid lineage-committed progenitors
. Proc Natl Acad Sci U S A
. 2015
;112
(31
):9638
-9643
.58.
Lopez-Verges
S
, Milush
JM
, Schwartz
BS
, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
. Proc Natl Acad Sci U S A
. 2011
;108
(36
):14725
-14732
.59.
Kvasnicka
HM
, Thiele
J
, Schmitt-Graeff
A
, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial
. J Clin Oncol
. 2001
;19
(12
):2994
-3009
.60.
Jiang
X
, Forrest
D
, Nicolini
F
, et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
. Blood
. 2010
;116
(12
):2112
-2121
.61.
Freud
AG
, Mundy-Bosse
BL
, Yu
J
, Caligiuri
MA
. The broad spectrum of human natural killer cell diversity
. Immunity
. 2017
;47
(5
):820
-833
.62.
Cichocki
F
, Taras
E
, Chiuppesi
F
, et al. Adaptive NK cell reconstitution is associated with better clinical outcomes
. JCI Insight
. 2019
;4
(2
):e125553
.63.
Miller
JS
, Lanier
LL
. Natural killer cells in cancer immunotherapy
. Annu Rev Cell Biol
. 2018
;3
(1
):77
-103
.64.
Shimasaki
N
, Jain
A
, Campana
D
. NK cells for cancer immunotherapy
. Nat Rev Drug Discov
. 2020
;19
(3
):200
-218
.65.
Bidikian
A
, Kantarjian
H
, Jabbour
E
, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
. Blood Cancer J
. 2022
;12
(10
):144
.© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal